Remove Gene Therapy Remove Licensing Remove Pharma Companies
article thumbnail

Laurus Labs and IIT Kanpur partner for new gene therapy products

Pharmaceutical Technology

Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. The company will also establish a GMP facility at IIT Kanpur’s Techno Park facility.

article thumbnail

Novartis adds gene therapy for blindness with Gyroscope buy

pharmaphorum

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect. The post Novartis adds gene therapy for blindness with Gyroscope buy appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

uniQure, CSL claim first okay for haemophilia B gene therapy

pharmaphorum

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults with the bleeding disorder in the US.

article thumbnail

UCB revs up its gene therapy drive with Handl acquisition

pharmaphorum

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

article thumbnail

BioArctic left in the cold as AbbVie abandons Parkinson’s pact

pharmaphorum

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. Interest in the target has also prompted a flurry of licensing deals. AZ/Takeda are meanwhile running phase 2 trials of their MEDI 1342 antibody candidate.

article thumbnail

The new pharma collaborations driving transformative research in oncology

pharmaphorum

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. Many novel therapies have been successfully developed through such partnerships. Case Study: From Technology Agreement to co-development and co-commercialisation partnership.

Research 132
article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e. Veeva is equally ‘super excited’.